Geron (GERN) 2.00 -0.055

Geron Corp
(GERN) 2.00 -0.055

Last Trade:	1.995	Day Range:	1.98 - 2.05
Trade Time:	08:02PM	52wk Range:	1.35 - 5.24
Prev. Close:	2.05	Market Cap:	262.29M
Open:	2.02	Div Yield:	0
Volume:	623443	PE:	-20
EPS:	-1.13

The Latest On GERN

Notable Put Options Activity in Geron 1/17/12 11:33am

Geron Corp Announces Phase 2 Data on Imetelstat Cancer Drug Won't be out Until Q4 2012 -Presentation Slides 1/11/12 11:12am

FDA Warns About Unproven Stem Cell Claims 1/8/12 7:11pm

Geron Corporation Appoints Graham Cooper as Chief Financial Officer 1/5/12 4:31pm

Geron Initiates Phase 2 Trial of GRN1005 in Brain Metastases From Breast Cancer 12/12/11 7:30am

End-of-Day Market Summary for November 16, 2011 11/16/11 4:15pm

J.P. Morgan Downgrades Geron, Removes 2012 PT 11/16/11 7:48am

Financial Breakfast: Morning News Summary for November 16, 2011 11/16/11 7:42am

JP Morgan Downgrades Geron to Neutral 11/16/11 6:30am

Even as Geron Shares Drop Other Players Converge on Stem Cells Space 11/15/11 12:37pm

Geron Presents Final Phase 1 Clinical Data on GRN1005 at AACR-NCI-EORTC 11/15/11 7:30am

Geron to Focus on Its Novel Cancer Programs 11/14/11 4:06pm

Notable Put Options Activity in Geron 1/17/12

Geron Corp Announces Phase 2 Data on Imetelstat Cancer Drug Won't be out Until Q4 2012 -Presentation Slides 1/11/12

FDA Warns About Unproven Stem Cell Claims 1/8/12

Geron Corporation Appoints Graham Cooper as Chief Financial Officer 1/5/12

Geron Initiates Phase 2 Trial of GRN1005 in Brain Metastases From Breast Cancer 12/12/11

End-of-Day Market Summary for November 16, 2011 11/16/11

J.P. Morgan Downgrades Geron, Removes 2012 PT 11/16/11

Financial Breakfast: Morning News Summary for November 16, 2011 11/16/11

JP Morgan Downgrades Geron to Neutral 11/16/11

Even as Geron Shares Drop Other Players Converge on Stem Cells Space 11/15/11

Geron Presents Final Phase 1 Clinical Data on GRN1005 at AACR-NCI-EORTC 11/15/11

Geron to Focus on Its Novel Cancer Programs 11/14/11

Financial Breakfast: Morning News Summary for November 16, 2011 11/16/11

Stocks to Watch for Wednesday 8/03/2011: Fresh 52 Week Highs and Lows 8/3/11

Stocks to Watch for Tuesday 8/02/2011: Fresh 52-Week Highs and Lows 8/2/11

Mad Money Lightning Round: Cramer Likes Schlumberger, Oracle 6/28/11

Stocks to Watch for 6/21/11: Fresh 52 Week Highs and Lows 6/21/11

Stocks to Watch for 6/20/11: Fresh 52-Week Highs and Lows 6/20/11

Stocks to Watch for 6/16/11: Fresh 52-Week Highs and Lows 6/16/11

Mad Money Lightning Round OT: Cramer Is A Seller of Quantum Corporation (QTM) (ASH, QTM, GERN, CRM, NFLX) 1/26/11

A Peek Into The Market Before The Trading Starts 1/10/11

EPIC! FDA OKs Human Clinical Trials of Embryonic Stem Cell Therapy; Trials Now Underway 12/9/10

Benzinga's Top Pre-Market NASDAQ Gainers (ACTI, GERN, TQNT, CCME) 10/12/10

Benzinga's Top Pre-Market NASDAQ Gainers (SGEN, CADC, GERN, CRUS) 9/29/10

End-of-Day Market Summary for November 16, 2011 11/16/11

J.P. Morgan Downgrades Geron, Removes 2012 PT 11/16/11

Financial Breakfast: Morning News Summary for November 16, 2011 11/16/11

JP Morgan Downgrades Geron to Neutral 11/16/11

UPDATE: Rodman & Renshaw Lowers PT to $4 on Geron 11/9/11

Rodman & Renshaw Lowers PT on Geron to $4 11/9/11

A Peek Into The Market Before The Trading Starts 1/10/11

Benzinga’s Top Pre-Market NASDAQ Losers (CRUS, ASML, GERN, COCO) 8/24/10

Geron (GERN) Stocks Not A Good Short-Term Buy 10/15/09

Trade GERN
NOW!

Partner Headlines

More Biotech Lessons Learned From JPM 2012 1/13/12

Geron's Stem Cell Bust Leaves Investors Holding the Bag 11/15/11

Narrower Loss at Geron - Analyst Blog 11/7/11

Geron Corp. Reports Operating Results (10-Q) 11/3/11

5 Stocks With Big Insider Buying 10/12/11

Geron Loss In-Line with Estimates - Analyst Blog 8/2/11

Analyst Interview - International Stem Cell - Analyst Blog 7/27/11

Mad Money Lightning Round: Grab Schlumberger 6/27/11

Geron Posts Wider Loss - Analyst Blog 5/2/11

Wider Q4 Loss at Geron - Analyst Blog 2/28/11

Press Releases

Geron Initiates Phase 2 Trial of GRN1005 in Brain Metastases From Breast Cancer 12/12/11 Business Wire Story

Geron Presents Final Phase 1 Clinical Data on GRN1005 at AACR-NCI-EORTC 11/15/11 Business Wire Story

Geron to Focus on Its Novel Cancer Programs 11/14/11 Business Wire Story

Geron Corporation Reports 2011 Third Quarter Financial Results and Events 11/3/11 Business Wire Story

Geron Announces Conference Call to Discuss Third Quarter Financial Results and Highlights 8/30/11 Business Wire Story

Geron Presents Clinical Data Update From GRNOPC1 Spinal Cord Injury Trial 8/30/11 Business Wire Story

Geron Corporation Appoints John A. Scarlett as Chief Executive Officer and Director 8/30/11 Business Wire Story

Geron Announces Presentation At ECTRIMS/ACTRIMS 8/30/11 Business Wire Story

Spinal Cord Injury Medical Leader Dr. Edward Wirth Joins InVivo Therapeutics as Chief Science Officer 8/30/11 Business Wire Story

Geron to Webcast Presentations at Upcoming Investor Conferences 8/30/11 Business Wire Story

Get the latest GERN stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Geron Corp stock price.

Geron Corp by YCharts

Geron (GERN) 2.00 -0.055

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On GERN

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social